Status:
COMPLETED
Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.
Lead Sponsor:
Cairo University
Conditions:
Active Non Segmental Vitiligo
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims at evaluating the effect of NB-UVB on tissue level of IL-15 and IL-15 receptor alpha subunit (IL-15Rα)(CD215) in active non segmental vitiligo. This in turn will shed light on the pote...
Detailed Description
Vitiligo is a T cell-mediated, autoimmune cutaneous disorder characterized by loss of functioning melanocytes from the basal layer of epidermis and/or hair follicles, leading to depigmented areas of t...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age: ≥ 18 years.
- Both genders.
- Type of Vitiligo: non segmental vitiligo (NSV).
- Active disease for less than 6 months (VIDA ≥ +2).
- No systemic or topical treatment for vitiligo for at least one month.
- Exclusion criteria:
- Patients less than 18 years.
- VIDA ≤ +1.
- Contraindications to phototherapy (precancerous conditions like
- Xeroderma pigmentosum , photosensitivity, history of arsenic intake,
- ionizing radiation, extensive previous exposure to PUVA, patients
- with a history of melanoma, atypical nevi, non-melanoma skin
- cancers and patients taking immunosuppressive medications ( Menter et al., 2010 and Mehta \& Lim, 2016).
- Pregnancy and lactation .
- Patients who received systemic or topical treatment for the past
- month.
- patients having any autoimmune diseases .
Exclusion
Key Trial Info
Start Date :
April 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05316987
Start Date
April 30 2022
End Date
July 30 2022
Last Update
August 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nourhan Emad
Cairo, Helwan, Egypt